艾伯塞拉生物

最新新闻

• 评级变动
  Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $9
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
  TipRanks · 2026/7/16
• Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。